中国学者发现三阴性乳腺癌患者疾病复发和总生存与原发肿瘤SPARC表达相关

　　骨黏连蛋白（osteonectin）是一种分泌性蛋白质，呈酸性又富含半胱氨酸残基（Secreted Protein Acidic and Rich in Cysteine，缩写：SPARC），在各种恶性肿瘤中的表达水平有所不同。然而，关于SPARC在三阴性乳腺癌患者中的预后价值鲜为人知。

　　2016年7月11日，美国《肿瘤标靶》在线发表中国医学科学院北京协和医学院肿瘤医院肿瘤研究所、中山大学肿瘤防治中心、华南肿瘤学国家重点实验室、肿瘤医学协同创新中心、首都医科大学附属北京地坛医院、山东烟台毓璜顶医院的研究成果，发现三阴性乳腺癌患者的疾病复发和总生存与原发肿瘤SPARC表达相关。

　　该研究使用免疫组织化学和免疫反应性评分（IRS）评估了211例三阴性乳腺癌患者原发性肿瘤的SPARC表达与长达10年的临床随访数据。

　　结果发现，52.1%的原发肿瘤检测到SPARC高表达（IRS≥3）。

　　SPARC高表达患者与SPARC低表达患者相比，无病生存（HR=1.58，95%CI：1.01～2.47，P=0.044）和总生存（HR=1.74，95%CI：1.06～2.85，P=0.029）显著较差。

　　此外，SPARC高表达为三阴性乳腺癌患者无病生存（HR=1.73，95%CI：1.10～2.73，P=0.018）和总生存（HR=1.90，95%CI：1.14～3.16，P=0.014）的独立预后因素。

　　因此，该研究结果表明，SPARC高表达可能是侵袭性较大的指标，并且可作为三阴性乳腺癌的预后因素。

Oncotarget. 2016 Jul 11. [Epub ahead of print]

SPARC overexpression in primary tumors correlates with disease recurrence and overall survival in patients with triplenegative breast cancer.

Zhu A, Yuan P, Du F, Hong R, Ding X, Shi X, Fan Y, Wang J, Luo Y, Ma F, Zhang P, Li Q, Xu B.

National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College (CAMS&PUMC), Beijing, China; Sun Yat-sen University Cancer center, The State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, China; Beijing Ditan Hospital, Capital Medical University, Beijing, China; Yuhuangding Hospital, Yantai, Shandong, China.

SPARC/osteonectin expression is reportedly altered in various malignancies. However, little is known regarding to the prognostic value of SPARC in triple-negative breast cancer (TNBC) patients. In this study, immunohistochemistry and immunoreactive scores (IRSs) were used to evaluate SPARC protein expression in primary tumors from 211 TNBC patients with up to 10 years of clinical follow-up data. High SPARC expression (IRS ≥3) was detected in 52.1% of primary tumors. Patients expressing high SPARC levels had worse disease-free survival (DFS) (HR=1.58, 95% CI: 1.01-2.47, P=0.044) and overall survival (OS) (HR=1.74, 95% CI: 1.06-2.85, P=0.029) than patients with lower SPARC levels. Furthermore, high SPARC expression was an independent prognostic factor for both DFS (HR=1.73, 95% CI: 1.10-2.73, P=0.018) and OS (HR=1.90, 95% CI: 1.14-3.16, P=0.014) in TNBC patients. These results suggest that increased SPARC expression may be an indicator of greater aggressiveness, and may serve as a prognostic factor for triple-negative breast cancer.

KEYWORDS: SPARC; osteonectin; prognosis; triple-negative breast cancer

PMID: 27421134

DOI: 10.18632/oncotarget.10532